Abbott (ABT) Q1 2026 Earnings
Abbott reported Q1 2026 revenue of $11.2B (+7.8% YoY), beat analyst consensus of $11.0B by $164.4M. Diluted EPS came in at $1.15 (+5.5% YoY), beat the $1.14 consensus by $0.01. Abbott reports across 4 business segments, led by Medical Devices, Established Pharmaceutical Products, and Diagnostic Products.
Q1 2026 Earnings FAQ
Common questions about Abbott's Q1 2026 earnings report.
Abbott (ABT) reported Q1 2026 earnings on April 16, 2026 before market open.
Abbott reported revenue of $11.2B and diluted EPS of $1.15 for Q1 2026.
Revenue beat the consensus estimate of $11.0B by $164.4M. EPS beat the consensus estimate of $1.14 by $0.01.
Compared to the same quarter a year prior, revenue grew 7.8% from $10.4B a year earlier and diluted EPS grew 5.5% from $1.09.
Abbott reports across 4 business segments, led by Medical Devices, Established Pharmaceutical Products, and Diagnostic Products. Segment-level financials are available on the company's metrics pages.
You can read the 8-K earnings release (0001628280-26-025365) directly on SEC EDGAR. The filing index links above go to sec.gov.